ストックスクリーナーアプリを入手
0.00
100.00%
-4.84
アフターアワーズ：
4.85
4.85
+
前日終値:
$4.84
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$633.18M
収益：
$25.81M
当期純損益:
$-188.12M
株価収益率:
0.00
EPS:
-1.4503
ネットキャッシュフロー:
$-183.77M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$7.91
Exscientia Plc Adr Stock (EXAI) Company Profile
EXAI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXAI
Exscientia Plc Adr
|
0.00 | 633.18M | 25.81M | -188.12M | -183.77M | -1.4747 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Exscientia Plc Adr Stock (EXAI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-09 | 開始されました | TD Cowen | Buy |
| 2024-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
Exscientia Plc Adr (EXAI) 最新ニュース
Exscientia's SWOT analysis: ai biotech stock faces merger challenges - Investing.com India
Exscientia's SWOT analysis: ai biotech stock faces merger challenges By Investing.com - Investing.com South Africa
Exscientia's SWOT analysis: ai-driven biotech stock faces merger challenges - Investing.com
Exscientia and Recursion Merge to Revolutionize Drug Discovery - TipRanks
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition - Investing.com
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition By Investing.com - Investing.com UK
Recursion, Exscientia shareholders back merger - Investing.com
Such Is The Power Of Verizon Communications Inc (NYSE: VZ) - Stocks Register
Quarterly Metrics: Quick and Current Ratios for Exscientia Plc ADR (EXAI) - The Dwinnex
Exscientia advances two drug programs with Sanofi By Investing.com - Investing.com South Africa
Exscientia advances two drug programs with Sanofi - Investing.com
How to interpret Exscientia Plc ADR (EXAI)’s stock chart patterns - US Post News
Recursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug Discovery - Yahoo Finance
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - MSN
Investing in Exscientia Plc ADR (EXAI) might be a great opportunity, but the stock is a bit undervalued - US Post News
Exscientia Plc ADR (EXAI)’s Market Momentum: Closing Strong at 5.06, Down -4.53 - The Dwinnex
Taking on analysts’ expectations and winning: Exscientia Plc ADR (EXAI) - SETE News
Exscientia's SWOT analysis: AI biotech stock faces merger, pipeline milestones - Investing.com
Exscientia Plc ADR (EXAI) expanding its growth trajectory ahead - SETE News
A stock that deserves closer examination: Exscientia Plc ADR (EXAI) - US Post News
Take off with Exscientia Plc ADR (EXAI): Get ready for trading - SETE News
Exscientia Plc ADR (EXAI)’s stock chart: A technical perspective - US Post News
Market Insights: Exscientia Plc ADR (EXAI)’s Notable Gain of 3.78, Closing at 5.22 - The Dwinnex
EXAI’s 52-Week Rollercoaster: From $3.80 to $7.91 – What’s Next for Investors? - The InvestChronicle
Closing Figures Unveiled: Exscientia Plc ADR (EXAI) Drop -1.02, Closes at 4.85 - The Dwinnex
EXAI (Exscientia Plc ADR) has impressive results - US Post News
Check out these key findings about Exscientia Plc ADR (EXAI) - SETE News
Exscientia Plc ADR (EXAI) Stock: A Year of Market Fluctuations - The InvestChronicle
Are Investors Keen On Selling Holdings In N2OFF Inc. (NASDAQ: NITO)? - Stocks Register
Daily Market Movement: Exscientia Plc ADR (EXAI) Sees a -1.77 Decrease, Closing at 5.56 - The Dwinnex
Ratios Reveal: Breaking Down Exscientia Plc ADR (EXAI)’s Financial Health - The Dwinnex
AI in Pharma and Biotech Market Projected Growth at 18.8% CAGR to Reach USD 13.1 billion by 2034 | Exclusive Research Report by Transparency Market Research Inc. - GlobeNewswire Inc.
Exscientia to Present at the Morgan Stanley 22 nd Annual Global Healthcare Conference - TT Nyhetsbyrån
Recursion Pharmaceuticals secures key shareholder support - Investing.com
What technical indicators reveal about EXAI stock - US Post News
Deeper Dive: Understanding Exscientia Plc ADR (EXAI) Through its Various Ratios - The Dwinnex
Have you been able to find a good deal on Exscientia Plc ADR’s shares? - US Post News
Exscientia Plc ADR (EXAI) Is Worth Accumulating At Current Levels - Stocks Register
EXAI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Market Resilience: Exscientia Plc ADR (EXAI) Finishes Strong at 5.00, Up 2.88 - The Dwinnex
Taking the lead: Exscientia Plc ADR (EXAI) - SETE News
Examining Exscientia Plc ADR (EXAI) stock is warranted - US Post News
Before Buying Exscientia Plc ADR (NASDAQ: EXAI) Stock, Read This First - Stocks Register
Exscientia stock downgraded to Hold amid Recursion merger - Investing.com
Recursion and Exscientia announce merger to enhance drug discovery - Investing.com
Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others (NASDAQ:EXAI) - Seeking Alpha
Views of Wall Street’s Leading Experts on Exscientia Plc ADR - SETE News
EXAI’s Debt-to-Equity Ratio at 0.06: What It Means for Exscientia Plc ADR’s Future - The InvestChronicle
Amazon (AMZN) Plunges 19.1% in a Month: Should You Buy the Dip? - Zacks Investment Research
Market Momentum: Exscientia Plc ADR (EXAI) Registers a -8.19 Decrease, Closing at 4.26 - The Dwinnex
Analyzing the Impact of Earnings Reports on Vivid Seats Inc Inc. (SEAT) Price Performance - The InvestChronicle
Exscientia Plc Adr (EXAI) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):